Neurodegenerative disorders affect millions worldwide. Resonant is developing accessible tools to help researchers, clinicians, & individuals detect biomarkers of neurodegeneration, supporting earlier diagnosis, treatment, and disease management.
Resonant is developing blood tests to support the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS. Building on our published proof-of-concept work in Alzheimer’s, we’ve completed a 300-sample study using patient blood samples collected across the three conditions (publication coming soon), and we’ve launched a larger longitudinal Alzheimer’s study in collaboration with the University of Kansas Alzheimer’s Disease Research Center (KU ADRC).
Our assays for Alzheimer’s, Parkinson’s, and ALS are currently available for Research Use Only. We are also exploring companion diagnostic opportunities with BioPharma partners interested in incorporating neuron type–specific biomarkers of neurodegeneration as endpoints in therapeutic studies.
Join our research waitlist to participate in upcoming studies on Alzheimer’s, Parkinson’s, and ALS.
Learn More
Explore our evolving solutions for healthcare systems, payers, and providers. Stay informed as we grow.
Learn More
Use our assays in academic or clinical research studies of neurodegeneration. Contact us to collaborate.
Learn More
When neurons die, they release DNA into the bloodstream. By identifying the neuron type the DNA came from, we gain insight into where neurodegeneration is occurring in the brain.
At Resonant, we analyze neuron type-specific methylation patterns—chemical markers that vary by cell type—to determine the neuron of origin and quantify the DNA as an indicator of neurodegeneration.
Different neurodegenerative diseases are typically associated with the death of distinct neuron types:
Cortical neurons in Alzheimer's disease
Dopamine neurons in Parkinson's disease
Spinal motor neurons in ALS
We're currently confirming the correlation between elevated neuron-derived DNA in the blood and disease using samples from patients with Alzheimer's, Parkinson's, and ALS.
Current diagnostic tools for neurodegenerative conditions are often limited—detecting disease too late, with insufficient sensitivity or accessibility for widespread impact. Earlier detection is critical. It supports timely access to clinical trials, proactive care planning, and the potential to influence outcomes while therapeutic windows remain open.
